LINC01549: A Drug Target / Disease Biomarker (G100505929)

Target Name: LINC01549

NCBI ID: G100505929

LINC01549

Other Name(s): Long intergenic non-protein coding RNA 1549, transcript variant 1 | long intergenic non-protein coding RNA 1549 | C21orf37

LINC01549: A Drug Target / Disease Biomarker

LINC01549 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is long non-coding RNA-protein LINC01549, and it is also known as NT-proP53. This protein is of interest as a potential drug target or biomarker, due to its involvement in a variety of cellular processes and its expression in several diseases, including cancer.

One of the key features of LINC01549 is its role in cell growth and division. This protein is a transcription factor that can bind to specific DNA sequences and regulate gene expression. It is well-known for its ability to induce cell proliferation and promote the formation of cancerous tumors.

In addition to its role in cell growth and division, LINC01549 is also involved in several other cellular processes that are important for human health, including immune response, metabolism, and stress resistance. For example, studies have shown that LINC01549 is involved in the regulation of cell apoptosis, which is the process by which cells undergo and die in response to various stimuli, including stress and DNA damage.

Another important function of LINC01549 is its role in the development and progression of certain diseases, including cancer. Studies have shown that LINC01549 is often expressed in various types of cancer, and that it is involved in the regulation of cellular processes that are important for cancer growth and progression. For example, LINC01549 has been shown to promote the growth and survival of cancer cells, and it has also been shown to inhibit the effectiveness of certain cancer treatments.

Due to its involvement in so many cellular processes, LINC01549 is a promising target for drug development. Researchers are currently working to develop small molecules and other compounds that can inhibit the activity of LINC01549 and prevent it from promoting the growth and survival of cancer cells. These compounds have the potential to be used as either anti-cancer drugs or as potential biomarkers for cancer.

In addition to its potential as a drug target, LINC01549 is also a potential biomarker for cancer. This is because its expression is often altered in cancer cells, and changes in LINC01549 expression levels can be an indication of the presence of cancer. For example, studies have shown that LINC01549 is often downregulated in various types of cancer, and that increasing LINC01549 expression levels can be an effective way to diagnose and treat cancer.

Overall, LINC01549 is a protein that is of great interest as a potential drug target or biomarker. Its involvement in cell growth and division, as well as its involvement in the development and progression of cancer, make it an attractive target for research and development. While further research is needed to fully understand the role of LINC01549 in these processes, its potential as a drug target and biomarker make it a promising area of study.

Protein Name: Long Intergenic Non-protein Coding RNA 1549

The "LINC01549 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01549 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets